Holistic management of patients with coronary artery disease undergoing coronary revascularization
Patrick W Serruys, Javaid Iqbal, Ayyaz Sulatn
Revista Argentina de Cardioangiología 2015;(02): 0072-0075 | Doi: 10.30567/RACI/201502/0072-0075
Palabras clave: coronary artery disease, coronary revascularization.
Este artículo no contiene abstract
Los autores declaran no poseer conflictos de intereses.
Fuente de información Colegio Argentino de Cardioangiólogos Intervencionistas. Para solicitudes de reimpresión a Revista Argentina de Cardioangiología intervencionista hacer click aquí.
Recibido | Aceptado | Publicado 2015-06-30
Coronary artery disease (CAD) remains the single most important cause of morbidity and mortality globally. In the recent decades, mechanical revascularization of coronary stenoses with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) has revolutionised the treatment of CAD. CABG has remained the predominant mode of revascularization during the 2nd half of 20th century. PCI has become the preferred method of revascularization in patients with single or double vessel disease, not involving left main stem. However, with the growing emphasis on mechanical revascularization, there is a concern that physicians and patients may become complacent about other aspects of managing CAD. This editorial highlights the two important aspects of managing CAD, optimal medical therapy (OMT) and life style modification, which are complimentary to coronary revascularization.
Optimal medical therapy OMT as 1st line therapy for CAD
MASS-II trial (n=611) has shown no difference in survival between OMT and revascularization (OMT 69%, CABG 74.9%, PCI 75.1%; p=0.09) at 10-year follow-up, despite difference in rates of myocardial infarction (MI) and repeat revascularization; however, the trial was underpowered for clinical outcomes1. COURAGE trial (n=2287) has shown that patients with significant one-, two- and three-vessel CAD without left main stem involvement randomised to OMT alone or to OMT plus PCI have no significant difference in the composite endpoint of death or non-fatal MI at 4.6 years follow-up2. Both groups were also equal in-terms of freedom from angina at 5-years2. Other studies comparing OMT with PCI have also reported no mortality benefit, increased nonfatal periprocedural MI, and reduced need for urgent revascularization with PCI compared with OMT3. CABG confers a survival benefit in patients with unprotected left main stem or three-vessel CAD, particularly in those with severe symptoms, early positive exercise tests, and/or impaired left ventricular function4. However, CABG with OMT did not show any mortality advantage over OMT in STITCH trial5. Therefore, OMT is the recommended initial choice in stable CAD patients without significant disease in left main stem or proximal left anterior descending artery6.
OMT for all patients undergoing revascularization
OMT is important and complimentary to revascularization therapy, whether it is PCI2 or CABG7. Progression of atherosclerosis continues after revascularization and is associated with deterioration of left ventricular function. Appropriate use of the secondary prevention therapy reduces mortality and MI after revascularization8. The use of OMT for secondary prevention, however, remains sub-optimal even in patients with established CAD who had undergone coronary revascularization, particularly after CABG9-12. In the EuroHeart Survey, a sizeable proportion of patients with chronic stable angina, managed medically or invasively, were not on OMT and this was associated with poor outcomes13.
A recently published post-hoc analysis of the SYNTAX trial14 has shown that prescription of OMT (defined as the combination of at least one antiplatelet drug, statin, beta-blocker and angiotensin converting enzyme inhibitor/angiotensin receptor blocker) was only 41% at the time of discharge after revascularization (PCI or CABG) and at 5-year only one-third patients in both treatment groups were taking OMT (PCI 40% and CABG 36%). OMT use was associated with a significant reduction in mortality and composite endpoint of death/MI/stroke. The study suggested that all the components of OMT are important for reducing adverse outcomes irrespective of revascularization strategy. OMT should therefore be considered for all patients with complex CAD treated with medical therapy, PCI or CABG, unless contraindicated.
Duration of dual antiplatelet therapy
Unless contraindicated, all patients undergoing PCI and stenting should receive dual antiplatelet therapy (DAPT) to reduce risk of stent thrombosis. For patients undergoing PCI for ACS, DAPT is recommended for 12 months. However, the duration and choice of anti-platelet agents for patients undergoing PCI for stable angina remains debatable and may depend on the choice of stent (BMS or DES). It is generally recommended to have a minimum of 1-month DAPT with BMS and 6-month DAPT with DES. However, 3-month DAPT with newer generation DES has also been approved in Europe15. Mauri et al. have reported reduction in MI and stent thrombosis with continuation of DAPT beyond 12-months, albeit at the expense of increased moderate-severe bleeding16. There was no difference in cardiovascular mortality; however, all-cause mortality was higher with continued DAPT. However, results of DAPT trial cannot be generalized. ARCTIC-Interruption, REAL-LATE, ZEST-LATE and PRODIGY have shown no benefit of continuing DAPT beyond 1-year17,18. Conversely, SECURITY, OPTIMIZE, EXCELLENT, RESET and ISAR-SAFE have shown that 3-6 months DAPT is non-inferior to 12-months DAPT19,20. An individualized risk-benefit assessment based on ischemic/thrombotic versus bleeding risk should guide the duration of DAPT, though defining these risks remains challenging. Patients with simple coronary lesion completely revascularized with a newer generation stent and no further events during the next 12-months is unlikely to require DAPT beyond 12-months.
Monitoring compliance and therapeutic effect
Patients with cardiovascular disease are likely to be on multiple drugs with the potential side effects and drug interactions. It is important to address any issues that a patient may have and stress the importance/rationale of each drug to improve patient adherence. The importance of OMT should be emphasised to patients at each clinical encounter to improve compliance. Moreover, hospital- and community-based programmes, such as the Get With The Guidelines and the Guidelines Applied in Practice initiative, may help to improve OMT prescription and patients’ compliance21.
Furthermore, it is also important to monitor the desired therapeutic effect of the medication. Farkouh et al. analysed data from diabetic patients in COURAGE, BARI-2D and FREEDOM and found that only 8% FREEDOM, 18% COURAGE and 23% BARI-2D patients achieved target for controlling blood pressure, cholesterol, diabetes and smoking cessation22. In CLARIFY registry23 (n=33177), nearly 41% of patients on beta-blockers had heart rate above 70 bpm. In another recent study of 366 patients with acute myocardial infarction, one-third of patients had LDL cholesterol levels above 2.5 mmol/L at 6-month follow-up24. Therefore, it is important to periodically monitor heart rate, blood pressure, lipid profile and HbAIc to optimise the secondary prevention therapy.
Life style modifications
The deleterious effects of smoking after PCI or CABG have been well described25-27, although some studies also suggested a “smokers’ paradox”28. However, the smoking status in most of these studies is usually taken at baseline and not collected at regular intervals. Conversely, smokers with established coronary artery disease may stop smoking permanently or intermittently. Therefore, assessing the impact of smoking status at baseline for long-term outcomes is not reliable. Additionally, most studies were performed in the era of PCI without stents or with bare metal stents and therefore provide little insight into the impact of smoking in patients undergoing revascularization with drug-eluting stents.
In a recent post-hoc analysis of the SYNTAX trial, it was shown that 20% of patients with complex CAD were smoking at baseline population29. 18% patientshad change in smoking habits during 5-year follow-up. The time of revascularization appears to be the most effective period to offer smoking cessation advice as suggested by 50% reduction of smoking habit between baseline and 6 months. Baseline smoking was associated with worse clinical outcomes due to a higher incidence of recurrent MI in both PCI and CABG arms but was not associated with MACCE. Interestingly, smoking status as time-dependant variable was an independent predictor of the composite endpoint of death/MI/stroke (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.3 to 2.5; p=0.001) and MACCE (HR: 1.4; 95% CI: 1.1 to 1.7; p=0.0002). This study confirms that there is no “smokers’ paradox”, at least in the context of patients with complex coronary artery disease undergoing coronary revascularization. Abstinence from smoking improves the outcomes achieved with coronary revascularization and all patients undergoing PCI or CABG should be encouraged to stop smoking indefinitely.
Other life style modifications
Early intervention should be targeted at eradicating poor-health behaviours by offering appropriate counselling that aids to adopt lifestyle changes, that diminish risk of cardiac adverse event, such as promoting weight loss, providing support to increase physical activity and adopting a healthy diet. However, limited data suggest that there is room for improvement in patient education about these life style changes30.
Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010;122:949-957.
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, Group CTR. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005;111:2906-2912.
Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-1616.
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-2555.
Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529-2540.
Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, Schmid JP. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17:1-17.
Okrainec K, Platt R, Pilote L, Eisenberg MJ. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol. 2005;45:177-184.
Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database. Circulation. 2007;116:I207-212.
Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.
Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305:1882-1889.
Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262-267.
Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, Feldman T, Stahle E, Escaned J, Banning AP, Gunn JP, Colombo A, Steyerberg EW, Mohr FW, Serruys PW. Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: Insights From the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial at the 5-Year Follow-Up. Circulation. 2015;131:1269-1277.
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-1402.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166.
Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-1382.
Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsegu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G, ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-1585.
Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G. Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy: The SECURITY Randomized Clinical Trial. J Am Coll Cardiol. 2014;64:2086-2097.
Stefanini GG, Siontis GC, Cao D, Heg D, Juni P, Windecker S. Short versus long duration of DAPT after DES implantation: a meta-analysis. J Am Coll Cardiol. 2014;64:953-954.
Xian Y, Pan W, Peterson ED, Heidenreich PA, Cannon CP, Hernandez AF, Friedman B, Holloway RG, Fonarow GC. Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J. 2010;159:207-214.
Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013;61:1607-1615.
Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012;7:e36284.
Martin SS, Gosch K, Kulkarni KR, Spertus JA, Mathews R, Ho PM, Maddox TM, Newby LK, Alexander KP, Wang TY. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J. 2013;165:26-33 e23.
van Domburg RT, Meeter K, van Berkel DF, Veldkamp RF, van Herwerden LA, Bogers AJ. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36:878-883.
Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR, Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. 1997;336:755-761.
de Boer SP, Serruys PW, Valstar G, Lenzen MJ, de Jaegere PJ, Zijlstra F, Boersma E, van Domburg RT. Life-years gained by smoking cessation after percutaneous coronary intervention. Am J Cardiol. 2013;112:1311-1314.
Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker’s paradox? Circulation. 2001;104:773-778.
Zhang YJ, Iqbal J, van Klaveren D, Campos CM, Holmes DR, Kappetein AP, Morice MC, Banning AP, Grech ED, Bourantas CV, Onuma Y, Garcia-Garcia HM, Mack MJ, Colombo A, Mohr FW, Steyerberg EW, Serruys PW. Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing Revascularization With PCI or CABG: The SYNTAX Trial at 5-Year Follow-Up. J Am Coll Cardiol. 2015;65:1107-1115.
Vachenauer R, Grunenfelder J, Plass A, Slankamenak K, Pantic L, Kisner D, Genoni M. Changing lifestyle habits as secondary prophylaxis after coronary artery bypass grafting. Heart Surg Forum. 2008;11:E243-247.
Revista Argentina de Cardioangiología intervencionista
Número 02 | Volumen 5 | Año 2015
Recordando a Liliana Grinfeld
Alfredo E Rodríguez
El último adiós a Liliana, una am...
Antonio A Pocoví
Holistic management of patients wit...
Patrick W Serruys y cols.
Embolización arterial de tumores y...
Luis García Nielsen y cols.
Perfusión miocárdica con tomograf...
Macarena C De Zan y cols.
Aneurisma arteria renal gigante. Ex...
Daniel Paolantonio y cols.
Manejo de la ruptura y atrapamiento...
Agustín Girassolli y cols.
Aneurisma degenerativo de aorta tor...
Omar Santaera y cols.
Carta del Presidente del Colegio Ar...
Arturo Fernández Murga
Colegio Argentino de Cardioangiólogos Intervencionistas
Viamonte 2146 6° (C1056ABH) Ciudad Autónoma de Buenos Aires | Argentina | tel./fax +54 11 4952-2117 / 4953-7310 |e-mail email@example.com | www.caci.org.ar
Colegio Argentino de Cardioangiólogos Intervencionistas | ISSN 2250-7531 | ISSN digital 2313-9307
La plataforma Meducatium es un proyecto editorial de Publicaciones Latinoamericanas S.R.L.
Piedras 1333 2° C (C1240ABC) Ciudad Autónoma de Buenos Aires | Argentina | tel./fax (5411) 4362-1600 | e-mail firstname.lastname@example.org | www.publat.com.ar
Meducatium versión 220.127.116.11 ST